From: Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
Title | NCT Number | Conditions | Status | Interventions |
---|---|---|---|---|
Lenalidomide in combination with CHOP in patients with untreated PTCL | NCT04423926 | PTCL, NOS AITL ALK− ALCL Phase III–IV ALK+ ALCL EATL | Recruiting Phase 1/Phase 2 | Drug: Lenalidomide Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisolone |
Treatment of newly diagnosed peripheral T-cell lymphoma | NCT03631862 | Newly diagnosed peripheral T-cell lymphoma | Recruiting Phase 4 | Drug: Apatinib Drug: CHOP Regimen |
Efficacy and safety of decitabine plus CHOP vs CHOP in patients with untreated peripheral T-cell lymphoma | NCT03553537 | Peripheral T-cell lymphoma | Not yet recruiting Phase 3 | Drug: Decitabine Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone |
CC486-CHOP in patients with previously untreated peripheral T-cell lymphoma | NCT03542266 | Previously untreated peripheral T-cell lymphoma | Active, not recruiting Phase 2 | Drug: CC-486 Administration Drug: CHOP Administration |
Chidamide with CHOP regimen for de Novo PTCL patients (CHOP: cyclophosphamide, etoposide, vincristine and prednisone; PTCL: Peripheral T cell lymphoma) | NCT03268889 | Peripheral T-cell lymphoma | Recruiting Not applicable | Drug: Chidamide |
Clinical trial of chidamide combined with CHOP in peripheral T-cell lymphoma patients | NCT02809573 | Peripheral T-cell lymphoma | Completed Phase 1 | Drug: Chidamide Drug: cyclophosphamide Drug: adriacin Drug: vincristine Drug: prednisone |
A Dose-Finding Study of Folotyn® (pralatrexate injection) Plus CHOP With peripheral T-cell lymphoma (PTCL) | NCT02594267 | Peripheral T-cell lymphoma | Active, not recruiting Phase 1 | Drug: Pralatrexate Injection |
Compare efficacy of CHOP versus fractionated ICED in transplant-eligible patients with previously untreated PTCL | NCT02445404 | Peripheral T-cell lymphoma | Recruiting Phase 2 | Drug: CHOP Drug: fractionated ICED |
Phase 1 dose finding study of belinostat for treatment of patients with peripheral T-cell lymphoma (PTCL) | NCT01839097 | Peripheral T-cell lymphoma | Completed Phase 1 | Drug: Belinostat Drug: CHOP |
Efficacy and safety of romidepsin CHOP vs CHOP in patients with untreated peripheral T-cell lymphoma | NCT01796002 | Peripheral T-cell lymphoma | Active, not recruiting Phase 3 | Drug: Romidepsin + CHOP Drug: CHOP |
ECHELON-2: a comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas | NCT01777152 | Anaplastic large-cell lymphoma Non-Hodgkin lymphoma T-cell lymphoma | Active, not recruiting Phase 3 | Drug: brentuximab vedotin Drug: CHOP/CHP |
CHOP vs GEM-P in 1st line treatment of T-cell lymphoma, multicentre phase II study | NCT01719835 | Peripheral T-cell lymphoma NOS Anaplastic large cell lymphoma, ALK-negative Angioimmunoblastic T-cell lymphoma Hepatosplenic Gamma/Delta T-cell lymphoma Enteropathy-associated T-cell lymphoma | Active, not recruiting Phase 2 | Drug: Cyclophosphamide Drug: Gemcitabine Drug: Doxorubicin Drug: Vincristine Drug: Prednisolone Drug: methylprednisolone Drug: Cisplatin |
Intensive chemo-immunotherapy as first line treatment in adult patients with peripheral T-cell lymphoma | NCT01679860 | Lymphoma, T-cell, peripheral | Completed Phase 2 | Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT Drug: Clin B (CHOP-CAMPATH) Chemo-immunotherapy |
Treatment of peripheral T-cell lymphoma | NCT01664975 | Peripheral T-cell lymphoma | Completed Phase 4 | Drug: GDPT regimen Drug: CHOP regimen |
Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients | NCT01420679 | Peripheral T-cell lymphoma | Terminated Phase 3 | Drug: Pralatrexate injection |
A phase 3 trial of E7777 in combination with CHOP compared with CHOP alone for the first-line treatment of peripheral T-cell lymphoma | NCT01355783 | Peripheral T-cell lymphoma | Withdrawn Phase 3 | Drug: E7777 |
A study of escalating doses of romidepsin in association with CHOP in the treatment of peripheral T-cell lymphomas | NCT01280526 | Peripheral T-cell lymphoma | Completed Phase 1/Phase 2 | Drug: Romidepsin and CHOP |
RAD001 combined with CHOP in newly diagnosed peripheral T-cell lymphomas | NCT01198665 | Peripheral T-cell lymphoma unspecified Anaplastic large cell lymphoma, ALK-negative Angioimmunoblastic T cell lymphoma Cutaneous T cell lymphoma | Completed Phase 1/Phase 2 | Drug: RAD001 (Everolimus) |
Safety study of darinaparsin in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to treat lymphoma | NCT01139359 | Lymphoma | Withdrawn Phase 1 | Drug: darinaparsin Drug: CHOP |
Endostar combined with CHOP regimen as first line chemotherapy for peripheral T cell lymphoma | NCT00974324 | T cell lymphoma | Unknown Phase 2 | Drug: endostar and CHOP |
The effectiveness of alemtuzumab given in combination with CHOP and ESHAP in patients newly diagnosed with peripheral T-cell lymphoma (PTCL) | NCT00930605 | Peripheral T-cell lymphoma | Completed Phase 2 | Drug: CHOP regimen alternate with ESHAP regimen Drug: Alemtuzumab |
CD4 in combination with CHOP in treating non-cutaneous peripheral T cell lymphoma | NCT00893516 | T-cell Lymphoma | Terminated Phase 2 | Biological: CHOP + CD4 Drug: CHOP |
SAHA + CHOP in untreated T-cell non-Hodgkin's lymphoma | NCT00787527 | Lymphoma | Completed Phase 1/Phase 2 | Drug: Zolinza (vorinostat) Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone |
Immunotherapy in peripheral T cell lymphoma—the role of alemtuzumab in addition to dose dense CHOP | NCT00725231 | Peripheral T cell lymphoma, unspecified Angioimmunoblastic lymphadenopathy Extranodal NK/T-cell Lymphoma | Unknown Phase 3 | Biological: alemtuzumab Drug: chemotherapy |
Alemtuzumab and CHOP in T-cell lymphoma | NCT00646854 | Lymphoma, T-cell, peripheral | Completed Phase 3 | Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF |
Alemtuzumab and CHOP chemotherapy for aggressive histological peripheral T-cell lymphomas | NCT00453427 | Peripheral T-cell lymphomas | Completed Phase 1/Phase 2 | Drug: Alemtuzumab (Campath-1H) |
The effectiveness of alemtuzumab combination with CHOP to treat patients newly diagnosed with PTCL | NCT00441025 | Peripheral T-cell lymphoma | Terminated Phase 2 | Drug: Alemtuzumab |
Bortezomib and CHOP in patients with advanced stage aggressive T cell or natural killer (NK)/T cell lymphomas | NCT00374699 | Peripheral T-cell lymphomas Non-hodgkin lymphoma | Completed Phase 1/Phase 2 | Drug: Velcade |
A pilot study to determine the safety of the combination of Ontak in combination with CHOP in peripheral T-cell lymphoma | NCT00337987 | Peripheral T-cell lymphoma | Completed Phase 2 | Drug: Ontak Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy |
A study of ONTAK and CHOP in newly diagnosed, peripheral T-cell lymphoma | NCT00211185 | Lymphoma, T-cell, peripheral | Completed Phase 2 | Drug: Denileukin diftitox Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Other: Pegfilgrastim |